How to buy Invitrocue (IVQ) shares
Learn how to easily invest in Invitrocue shares.
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Invitrocue Limited is a biotechnology business based in Australia. Invitrocue shares (IVQ) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian Dollars. Invitrocue has a market cap (total outstanding shares value) of $34.7 million. If you're looking to buy shares, check out the steps below.
How to buy shares in Invitrocue
- Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the Australian Securities Exchange (ASX). Our table below can help you choose.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
- Search for Invitrocue . Find the share by name or ticker symbol: IVQ. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Invitrocue reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At today's price, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
- Check in on your investment. Congratulations, you own a part of Invitrocue . Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
Invitrocue stock price (ASX:IVQ)Use our graph to track the performance of IVQ stocks over time.
Invitrocue shares at a glance
|52-week range||$0.06 - $0.06|
|50-day moving average||$0.06|
|200-day moving average||$0.06|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.007|
Compare share trading platforms
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Is it a good time to buy Invitrocue stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|Gross profit TTM||$252,858|
|Return on assets TTM||-167.33%|
|Return on equity TTM||-1214.48%|
|Market capitalisation||$34.7 million|
TTM: trailing 12 months
Invitrocue share dividends
We're not expecting Invitrocue to pay a dividend over the next 12 months.
Have Invitrocue 's shares ever split?
Invitrocue 's shares were split on a 1:52 basis on 19 May 2015. So if you had owned 52 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Invitrocue shares – just the quantity. However, indirectly, the new 5100% higher share price could have impacted the market appetite for Invitrocue shares which in turn could have impacted Invitrocue 's share price.
Invitrocue share price volatility
Over the last 12 months, Invitrocue 's shares have ranged in value from as little as $0.06 up to $0.06. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Invitrocue 's is 0.3467. This would suggest that Invitrocue 's shares are less volatile than average (for this exchange).
Invitrocue Limited engages in the research and experimental development on biotechnology, life, and medical science primarily in Singapore, Australia, China, Hong Kong, and Germany. The company develops Onco Patient-Derived Organoid (PDO) test, a personalized cancer treatment for cancer patients; and 3D CelluSponge series, a 3D in-vitro platform technology for various applications, including 3D cell culture, hepatocyte culture, in-vitro drug metabolism and pharmacokinetics assays and toxicology, stem cell differentiation, PDO, and pathogen infection and detection. It also provides respiratory disease, and customized assays and disease modelling services. Invitrocue Limited was founded in 2012 and is headquartered in Singapore.
Stocks similar to Invitrocue
Invitrocue in the news
Frequently asked questions
More guides on Finder
How to invest in the X2M Connect IPO
Everything we know about the X2M Connect IPO, plus information on how to buy in.
How to buy Industrial Minerals (IND.AU) shares
Steps to owning and managing Industrial Minerals shares.
How to invest in the SSH Group IPO
Everything we know about the SSH Group IPO, plus information on how to buy in.
Why is the CSL share price bouncing back?
Shares in biotech giant CSL are up 6% in the past year and have seen a bounceback over the last few sessions.
How to invest in the Iris Metals IPO
Everything we know about the Iris Metals IPO, plus information on how to buy in.
Why is the Crown Resorts (CWN) share price sinking?
Shares in the casino operator have lost a quarter of their value from a year-high hit in May.
Today’s ASX top stocks: Damstra Holdings (DTC ↑15.5%), DDH1 (DDH ↑13.6%)
The 10 biggest movers on the ASX for Friday 23 July 2021.
How to invest in the Li-S Energy IPO
Everything we know about the Li-S Energy IPO, plus information on how to buy in.
How to invest in the Clarity Pharmaceuticals IPO IPO
Everything we know about the Clarity Pharmaceuticals IPO IPO, plus information on how to buy in.
How to invest in the TEK-Ocean Group IPO
Everything we know about the TEK-Ocean Group IPO, plus information on how to buy in.
Ask an Expert